<DOC>
	<DOCNO>NCT01347073</DOCNO>
	<brief_summary>This non-randomized , open-label study approximately one year duration consist short term NaPBA HPN-100 switchover part involve two overnight stay follow 12-month long term treatment period involve monthly visit .</brief_summary>
	<brief_title>Study Safety , Pharmacokinetics Efficacy HPN-100 , Pediatric Subjects With Urea Cycle Disorders ( UCDs )</brief_title>
	<detailed_description>This open-label study consist 10-day switch-over period subject switch prescribe dose sodium phenylbutyrate ( BUPHENYLTM NaPBA ) dose HPN-100 deliver amount active ingredient , PBA , follow long-term treatment HPN-100 12 month . The study design capture information important evaluating safety , Pharmacokinetics , efficacy recognize sample limitation young child current standard care . Patients eligible study include pediatric patient 29 day &lt; 6 year age either diagnose clinically suspect Urea Cycle Disorders ( UCD ) receive stable dose powder formulation NaPBA . Subjects clinically stable receive stable dose NaPBA powder least 5 day time enrollment . During switch-over part study , subject switch NaPBA HPN-100 one step two overnight stay 24 hour blood sampling , first Day 1 , still take NaPBA , second approximately Day 10 take HPN-100 . Subjects continue long-term treatment phase 12 month duration .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Urea Cycle Disorders , Inborn</mesh_term>
	<mesh_term>Glycerol</mesh_term>
	<mesh_term>4-phenylbutyric acid</mesh_term>
	<criteria>Male female subject 29 day &lt; 6 year old . If subject bear prematurely , calculation low age limit begin correct gestational age 40 week . Signed informed consent subject 's legally acceptable representative Suspected confirm UCD diagnosis subtype , except NAGS deficiency On stable dose NaPBA powder least 5 day Day 1 Not receive sodium benzoate least 5 day Day 1 No concomitant illness would preclude safe participation judge investigator Able receive medication orally Has undergone liver transplantation , include hepatocellular transplantation Judged sufficiently stable compliant diet treatment suitable enrollment Screening ammonia level &gt; 100 μmol/L sign symptom indicative hyperammonemia ; subject may rescreened ammonia control clinically stable , discretion investigator Use investigational drug within 30 day Day 1 Active infection ( viral bacterial ) condition may increase ammonia level Any clinical laboratory abnormality Grade 3 great severity accord Common Terminology Criteria Adverse Events ( CTCAE ) v4.03 , except Grade 3 elevation ammonia liver enzymes , define level 520 time ULN ( upper limit normal ) alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , gamma glutamyl transpeptidase ( GGT ) clinically stable subject Any clinical laboratory abnormality medical condition , discretion investigator , may put subject increase risk participate study Known hypersensitivity PAA PBA Liver transplant , include hepatocellular transplant Currently treat Carbaglu® ( carglumic acid )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Urea Cycle Disorder</keyword>
	<keyword>UCD</keyword>
	<keyword>GT4P</keyword>
	<keyword>Buphenyl</keyword>
	<keyword>hyperammonemia</keyword>
	<keyword>sodium phenylbutyrate</keyword>
</DOC>